Ultragenyx Pharmaceutical reported $8.63M in Cost of Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.14M 531K
Agios Pharmaceuticals AGIO:US USD 517K 82K
Alnylam Pharmaceuticals ALNY:US USD 41.12M 308K
Biocryst Pharmaceuticals BCRX:US USD 3.61M 3.37M
Biomarin Pharmaceutical BMRN:US USD 116.29M 6.84M
Esperion Therapeutics ESPR:US USD 6.51M 2.67M
Insmed INSM:US USD 13.47M 2.92M
IONIS PHARMACEUT IONS:US USD 1.52M 3.23M
Karyopharm Therapeutics KPTI:US USD 980K 41K
Kyowa Hakko Kirin 4151:JP JPY 20.77B 455M
MacroGenics MGNX:US USD 3.14M 741K
Moderna Inc MRNA:US USD 1.1B 281M
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Ptc Therapeutics PTCT:US USD 14.01M 4.37M
Puma Biotechnology PBYI:US USD 12.5M 2.42M
Regeneron Pharmaceuticals REGN:US USD 317.8M 20.7M
Sarepta Therapeutics SRPT:US USD 39.95M 2.16M
Ultragenyx Pharmaceutical RARE:US USD 8.63M 361K
Vertex Pharmaceuticals VRTX:US USD 289.4M 27.6M